Overview
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice
Status:
Completed
Completed
Trial end date:
2017-04-24
2017-04-24
Target enrollment:
0
0
Participant gender:
All
All
Summary
Defining Which Remission Criterion at Month 6 Predicts Remission at Month 12 in a Real Life Clinical Practice, in a Cohort of Rheumatoid Arthritis Patients Treated with EtanerceptAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
PfizerTreatments:
Etanercept
Criteria
Inclusion Criteria:1. Patients with active RA who start treatment with etanercept according to the
prevailing reimbursement criteria and dosing in line with the SmPC.
1. First cohort: Etanercept is the first biological product prescribed.
2. Second cohort: Etanercept is the second biological product prescribed.
2. Capable of understanding and willing to provide signed and dated written, voluntary
informed consent before any protocol-specific procedures are performed.
3. Eighteen (18) years of age or older at time of consent.
Exclusion Criteria:
1. History of or current psychiatric illness that would interfere with the subject's
ability to comply with protocol requirements or to give informed consent.